|Bid||3.58 x 800|
|Ask||4.43 x 3100|
|Day's Range||4.0200 - 4.1900|
|52 Week Range||3.2200 - 13.9100|
|Beta (3Y Monthly)||0.85|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 3, 2017 - Aug 7, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.00|
Study results indicated that orally-administered CPI-818 produced tumor regression in three of three companion dogs with spontaneous, naturally occurring T-cell lymphomas, without significant toxicity. Based on these data, Corvus plans to submit an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in early 2019.
Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced that it has initiated patient enrollment in the second arm of its ongoing Phase 1/1b dose-escalation study. This arm is evaluating CPI-006, a humanized monoclonal antibody directed against CD73, in combination with CPI-444, a selective and potent inhibitor of the adenosine A2A receptor. The Phase 1/1b study is currently enrolling patients with non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and other cancers who have failed standard therapies. The first arm of the study is evaluating CPI-006 as a single agent and has dosed patients in several cohorts of escalating doses.
Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is also making good progress. The company is also developing gene therapies.
BURLINGAME, Calif., Nov. 12, 2018 -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of.
Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced updated clinical and biomarker data from ongoing Phase 1/1b studies of its lead programs, CPI-444 and CPI-006. Updated results from its Phase 1/1b clinical trial of CPI-444 in patients with treatment-refractory renal cell carcinoma (RCC) demonstrated an overall survival (OS) of 88 percent at more than 20 months follow-up with CPI-444 administered in combination with atezolizumab. The clinical data were presented in an oral session at the Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting in Washington, D.C., by Lawrence Fong, M.D., study investigator and leader of the Cancer Immunotherapy Program at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center.
Event will provide a review of new CPI-444 and CPI-006 data presented at SITC & ESMO BURLINGAME, Calif., Nov. 05, 2018 -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a.
The Burlingame, California-based company said it had a loss of 36 cents per share. Corvus shares have dropped 21 percent since the beginning of the year. The stock has declined 41 percent in the last 12 ...
Corvus Pharmaceuticals, Inc. (CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of precisely targeted oncology therapies, today announced financial results for the third quarter ended September 30, 2018, and provided a business update. “We continue to make significant progress in the clinic both with CPI-444 and with CPI-006,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. This includes biomarker data for CPI-444 that our team presented at the ESMO 2018 Congress on October 22, 2018.
On a per-share basis, the Burlingame, California-based company said it had a loss of 40 cents. Corvus shares have fallen 9 percent since the beginning of the year. In the final minutes of trading on Thursday, ...
Stock Monitor: Corvus Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 19, 2018 / Active-Investors.com has just released a free research report on Checkpoint Therapeutics, Inc. (NASDAQ: CKPT ...